1. ALLA AKTIER
  2. NYHETER
  3. LIPUM

Lipum

Nyheter Lipum Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Lipum AB - Report from the Extraordinary General Meeting

MARKN.

An Extraordinay General Meeting (the ”EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (”Lipum” or the “Company”) today resolved to approve the Board of Directors’ resolution on a rights issue of up to 2,870,334 new shares.

On 8 June 2023, the Board of Directors resolved, subject to approval by an EGM, on a rights issue of up to 2,870,334 new shares at a subscription price of SEK 9.20 per share (the “Rights Issue”). The EGM today approved the Board of Directors’ resolution on the Rights Issue.

The minutes from the EGM (in Swedish) will be available on Lipum’s website, www.lipum.se/bolagsstyrning/.

Contacts
Einar Pontén, CEO
E-post: einar.ponten@lipum.se
Mobile: +46 70 578 34 95
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum AB - Report from the Extraordinary General Meeting

Datum 2023-06-27, kl 13:45
Källa MFN
Bifogade filer
Lipum AB - Report from the Extraordinary General Meeting